Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP12 | P39900 | 2/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.45 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.45 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.45 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.45 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.45 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.45 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.45 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14943552 | 0.89 | NPC1 (0.53) | NPC1RAB9AMMP1MMP2MMP9 | |
| SCHEMBL15338736 | 0.88 | NPC1 (0.52) | NPC1RAB9AMMP1MMP2MMP9 | |
| SCHEMBL15338745 | 0.88 | NPC1 (0.55) | NPC1RAB9AMMP1MMP2MMP9 | |
| SCHEMBL8132821 | 0.87 | ALDH1A1 (0.51) | NPC1RAB9AMMP1MMP2MMP9 | |
| SCHEMBL12467248 | 0.87 | NPC1 (0.51) | NPC1RAB9AMMP1MMP2MMP9 | |
| SCHEMBL12401144 | 0.84 | GRM5 (0.49) | NPC1RAB9AMMP1MMP2MMP9 | |
| SCHEMBL12401138 | 0.84 | POLB (0.53) | RAB9AALDH1A1 | |
| SCHEMBL12404561 | 0.83 | SYK (0.52) | NPC1RAB9AATMCTSKELANE | |
| SCHEMBL12401266 | 0.81 | RAB9A (0.53) | RAB9AALDH1A1HDAC1HDAC6 | |
| SCHEMBL27645858 | 0.78 | NPC1 (0.60) | NPC1RAB9AMMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | NPC1 252/4885RAB9A 2004/4885MMP1 523/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | NPC1 252/4885RAB9A 2004/4885MMP1 523/4885 |
| US-20100272681-A1 | Inhibitors of Serine Proteases | SERPINB1, PRSS1, SPINT2 | NPC1 622/4885RAB9A 3172/4885MMP1 871/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | NPC1 211/4885RAB9A 2014/4885MMP1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.